Literature DB >> 9154737

LSD before Leary. Sidney Cohen's critique of 1950s psychedelic drug research.

S J Novak1.   

Abstract

In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychotomimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were administering it to cure neuroses and alcoholism and to enhance creativity. Cohen's 1960 study of LSD effects concluded that the drug was safe if given in a supervised medical setting, but by 1962 his concern about popularization, nonmedical use, black market LSD, and patients harmed by the drug led him to warn that the spread of LSD was dangerous. The subsequent government crackdown and regulation of LSD preceded the 1960s drug movement and was prompted by medical, not social, concerns.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9154737     DOI: 10.1086/383628

Source DB:  PubMed          Journal:  Isis        ISSN: 0021-1753            Impact factor:   0.688


  7 in total

Review 1.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

2.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

Review 3.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

Review 4.  Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.

Authors:  Rainer Kraehenmann
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine.

Authors:  David M O'Shaughnessy; Ilana Berlowitz; Robin Rodd; Zoltán Sarnyai; Frances Quirk
Journal:  Ther Adv Psychopharmacol       Date:  2021-01-25

6.  Amazonian Medicine and the Psychedelic Revival: Considering the "Dieta".

Authors:  David M O'Shaughnessy; Ilana Berlowitz
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

7.  Supple bodies, healthy minds: yoga, psychedelics and American mental health.

Authors:  Lucas Richert; Matthew DeCloedt
Journal:  Med Humanit       Date:  2018-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.